Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/5/2025 | $30.00 | Neutral → Buy | UBS |
| 12/7/2023 | $35.00 | Neutral | UBS |
| 12/8/2022 | $65.00 → $40.00 | Overweight → Neutral | Piper Sandler |
| 11/18/2022 | $45.00 | Outperform | Raymond James |
| 8/25/2022 | $65.00 | Outperform | Credit Suisse |
| 2/4/2022 | $80.00 | Overweight | Piper Sandler |
| 1/25/2022 | $141.00 → $125.00 | Outperform | Oppenheimer |
| 8/10/2021 | $55.00 → $65.00 | Underperform | Credit Suisse |
4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with established laboratory services and therapeutic development businesses, today announced it presented updated data in the Head and Neck Cancer Track during the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting Rapid Oral Abstract Session, scheduled from 4:30 p.m. to 6:00 p.m. CDT in Hall D1 at McCormick Place in Chicago. The abstract, entitled "FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), Abstract #6020," will present updated preliminary data from the Company's open-label, randomized Phase 2 study (NCT0633
Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that its full abstract has been released on the ASCO 2026 website. The abstract will be presented within the Head and Neck Cancer Track of the American Society of Clinical Oncology (ASCO) Rapid Oral Abstract Session on June 1, 2026, from 4:30pm to 6:00pm (CDT) in Hall D1 of McCormick Place, Chicago. The abstract is entitled "FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), Abstract #6020". It presents interim data from th
New solution helps guide cancer therapy selection and dosing strategies to support safer, more effective patient care FoundationOne PGx includes genes associated with the metabolism of medicines that have strong clinical evidence and actionable guidelines, including DPYD Foundation Medicine, Inc., a global, patient-focused precision medicine company, today announced plans to launch FoundationOne®PGx, a pharmacogenetic (PGx) offering to identify genetic differences that influence how medicines are metabolized and processed by the body. FoundationOne PGx will be offered in the United States through a partnership with Fulgent Genetics, Inc. (NASDAQ:FLGT) and will be available to order thro
UBS upgraded Fulgent Genetics from Neutral to Buy and set a new price target of $30.00
UBS initiated coverage of Fulgent Genetics with a rating of Neutral and set a new price target of $35.00
Piper Sandler downgraded Fulgent Genetics from Overweight to Neutral and set a new price target of $40.00 from $65.00 previously
SCHEDULE 13D/A - Fulgent Genetics, Inc. (0001674930) (Subject)
8-K - Fulgent Genetics, Inc. (0001674930) (Filer)
S-8 - Fulgent Genetics, Inc. (0001674930) (Filer)
4 - Fulgent Genetics, Inc. (0001674930) (Issuer)
Proposed acquisition will add new anatomic pathology services, proprietary PCR tests and a national client base Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it has entered into a definitive agreement to acquire selected assets of Bako Diagnostics ("Bako"), a premier pathology laboratory headquartered in Alpharetta, GA and to acquire StrataDx, a premier dermatopathology laboratory located in Lexington, MA. Fulgent will acquire certain assets of Bako Diagnostics and will acquire StrataDx for a total combined purchase price of approximately $55.5 m
NEW YORK, March 7, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 100 are more representative of the mega-cap market space. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P
PRESS RELEASE - 10/06/2024, 07:00 CEST Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing Mechelen, Belgium 10 June 2024 – Biocartis NV (the ‘Company' or ‘Biocartis'), an innovative molecular diagnostics company, is pleased to announce the appointment of Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as Vice President Global Marketing. Gina Wallar, PhD as Chief Business Officer: Gina Wallar was appointed as Biocartis' Chief Business Officer on 15 April 2024 and will be responsible for Biocartis' business development and partnering initiatives, as well as US commercialization. Dr. Wallar has more than 20 year
Reiterates revenue guidance for fiscal year 2026 Executed on stock repurchase program; purchased approximately 2.6 million shares in the first quarter of 2026 using $40.1 million in cash Revenue of $71.1 million GAAP gross profit of $21.5 million, or GAAP gross margin of 30.2%; Non-GAAP gross profit of $23.0 million, or Non-GAAP gross margin of 32.3% GAAP loss of $24.8 million, or $(0.80) per share; Non-GAAP loss of $11.0 million, or $(0.36) per share Ended the first quarter of 2026 with $604.7 million of cash, cash equivalents, restricted cash, and investments in marketable securities, excluding an anticipated tax refund of approximately $106 million Fulgent Genetics, In
Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its first quarter 2026 financial results before the market opens on Friday, May 1, 2026. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions. The call may be accessed through a live audio webcast on the Investor Relations section of the Company's website, http://ir.fulgentgenetics.com. An audio replay will be available at the same location. About Fulgent Fulgent is a
Revenue of $83.3 million, growing 9% year-over-year GAAP gross profit of $32.6 million, or GAAP gross margin of 39.1%; Non-GAAP gross profit of $34.2 million, or Non-GAAP gross margin of 41.0% GAAP loss of $23.4 million, or ($0.76) per share; Non-GAAP income of $5.2 million, or $0.16 per share Ended the year with $705.5 million of cash, cash equivalents, restricted cash, and investments in marketable securities, excluding an anticipated tax refund of approximately $106.3 million Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announce
SC 13D/A - Fulgent Genetics, Inc. (0001674930) (Subject)
SC 13G/A - Fulgent Genetics, Inc. (0001674930) (Subject)
SC 13G/A - Fulgent Genetics, Inc. (0001674930) (Subject)